The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the recombinant human monoclonal antibody Yervoy (ipilimumab) as a first-line ...
The European Commission (EC) has granted Bristol Myers Squibb (BMS) approval for its Opdivo (nivolumab) combination with gemcitabine and cisplatin for the first-line treatment of adult patients with ...
Biologic along with MTX may be used after DMARD inadequate response. Bristol-Myers Squibb (BMS) obtained approval from the European Commission for Orencia® in combination with methotrexate (MTX) for ...
Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been approved by the European Commission (EC) to treat hepatocellular carcinoma (HCC), the most common type of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results